Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain

AAPS Journal

Volumn 14, Issue 2, 2012, Pages 168-175

  Dutta, Sandeep ^a   Hosmane, Balakrishna S ^b   Awni, Walid M ^a  

^a ABBOTT LABORATORIES   (United States)

^b NORTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

Dose response; Logistic regression; Modeling; Neuropathic pain; Population analyses

Indexed keywords

NICOTINE; PLACEBO; TEBANICLINE;

ABNORMAL DREAMING; ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXPLANATORY VARIABLE; FEMALE; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; NONLINEAR MIXED EFFECT MODEL; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SMOKING; STATISTICAL MODEL; TREATMENT DURATION; VOMITING;

AGED; AZETIDINES; DIABETES MELLITUS; DIABETIC NEUROPATHIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; NONLINEAR DYNAMICS; PYRIDINES; TREATMENT OUTCOME;

EID: 84860711411     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9328-7     Document Type: Article

References (19)

1. Woolf CJ. Neurobiology of disease. Pain. 2000;7:504-10.
2. Turk DC, Wilson HD, CahanaA. Treatment of chronic non-cancer pain. Lancet. 2011;377:2226-35.
3. Poncelet AN. Diabetic polyneuropathy: risk factors, patterns of presentation, diagnosis, and treatment. Geriatrics. 2003;58 (6):16-30. (Pubitemid 36682478)
4. Cymbalta® (Duloxetine HCl) [prescribing information]. Indianapolis, IN: Eli Lilly; 2001
5. Lyrica® (Prebabalin) [prescribing information]. Vega Baja, PR: Pfizer Inc.; 2001
6. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndrome. Pain. 1997;73:123-39. (Pubitemid 27491673)
7. Fishbain DA, Cutler R, Rosomoff HL, et al. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med. 2000;1(4):310-16.
8. Bannon AW, Decker MW, Curzon P, et al. ABT-594 [(R)-5-(2- azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Therapeut. 1998;285:787-94. (Pubitemid 28237462)
9. Rowbotham MC, Duan WR, Thomas J, et al. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain. 2009;146:245-52.
10. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11(3):153-62. (Pubitemid 38373032)
11. Farrar JT, Young JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-58. (Pubitemid 33016608)
12. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283-91. (Pubitemid 38859657)
13. Othman AA, Garimella T, Dutta S, et al. Non-linear mixed-effects model-based meta-analyses of the efficacy at end-of-trials for drugs evaluated for treatment of diabetic neuropathic pain. Poster presented at the American Conference on Pharmaco-metrics; 2011 April 3-6; San Diego, CA. Abstract published in J Clin Pharmacol. 2011;51(9):1351.
14. Beal S, Sheiner L. NONMEM. San Francisco: NP Group; 1998.
15. Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994;56(3):309-22. (Pubitemid 24323923)
16. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther. 1996;60(6):619-35. (Pubitemid 27025909)
17. Dutta S, Diderichsen PM, Liu W. Clinical trial simulation of outcome after accounting for high dropout typical of acute pain studies. Poster presented at the American College of Clinical Pharmacology 40th Annual Meeting, 2011 September 11-13, Chicago, IL. Abstract published in J Clin Pharmacol. 2011;51 (9):1367.
18. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69(2):374-9.
19. Moore RA, Moore OA, Derry S, et al. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther. 2008;10(2):1-5.